
    
      Subjects should continue on the treatment regimen that the subject was receiving in the prior
      study. Dose changes of any of the prior therapies subjects were receiving on the previous
      protocol are allowed after medical monitor approval. The day 1 visit for this study should
      coincide with the last treatment visit for the study the subject will be enrolling from (≤ 7
      days post last visit of parent study). The subjects will be followed according to the local
      institution's standard of care and will be required to return to the institution every 12
      weeks (± 7 days) to review adverse events (AEs), collect concomitant medications, confirm
      that no discontinuation criteria are met, return all dispensed study drug and to receive more
      study drug if applicable. All AEs (new and ongoing from the study the subject is enrolling
      from) and Serious Adverse Events (SAEs) (including death), will be collected from the time
      the subject signs the consent form until the end of study visit.
    
  